Machine Learning

Camping app The Dyrt is giving away $500,000 in PRO subscriptions. A look at the high-stakes strategy to capture the booming RV market.

Annexon Biosciences spotlights its novel C1q inhibitor, Vonaprument, aiming to be the first therapy to preserve vision in geographic atrophy patients.

Partnering with Riskified, the travel platform boosted approvals to 93%, enabling expansion and enhancing customer experience in a high-fraud region.

Watchmaker Genomics is repurposing CRISPR, not for editing genes, but to make DNA sequencing faster, cheaper, and more reliable than ever before.

A new oral drug from Nimbus Therapeutics uses AI-driven precision to fight inflammation and repair tissue, offering new hope for millions with IBD.

Cyrano Therapeutics' CYR-064 shows promise in a Phase 2 study, potentially becoming the first approved drug for persistent post-viral smell loss.

As Revvity execs prepare for key conferences, investors will watch for clues on AI strategy, growth guidance, and margin recovery after a mixed 2025.

An independent board again backs the safety of BriaCell's metastatic breast cancer therapy in a pivotal Phase 3 trial, boosting hope for a new treatment.

Israeli tech firm Nanox will debut its low-cost Nanox.ARC imaging system in Europe, pairing it with AI that spots chronic disease in routine scans.

Continu launches 'Experts,' an AI tool that securely connects to Google Drive and OneDrive, delivering instant, permission-aware answers in Slack and Teams.

A new supply agreement for the rare isotope Actinium-225 between NorthStar and BIOEMTECH promises to break a critical bottleneck in radiopharmaceutical R&D.

New research reveals a startling link between AI's excessive permissions and a surge in security breaches, forcing a rethink of enterprise trust and access.

With an $8M Series A, QuadSci's AI analyzes user behavior to predict churn up to 18 months out, promising to fix the SaaS industry's revenue problem.

A new series from A3 and BBC StoryWorks moves beyond efficiency to show how automation is augmenting human lives in healthcare, education, and more.

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.

Vexcel announces its 2026 plan to capture 5.2M km² of U.S. aerial imagery, powering critical industries from insurance to AI with unprecedented detail.

A new program in Michigan uses AI to analyze existing CT scans, detecting silent heart risks and connecting patients to care before symptoms even appear.

A new five-year deal will leverage patient-derived stem cells and AI to revolutionize the hunt for Alzheimer's cures, aiming to bridge a critical gap.

A new partnership aims to manufacture a life-saving gene therapy for NKH, a devastating rare disorder, driven by a family's relentless advocacy.

After a $6M cash infusion and leadership change, the diagnostics firm is selling its flagship product to chase a high-risk, high-reward U.S. market.